Compare GMAB & GGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | GGG |
|---|---|---|
| Founded | 1999 | 1926 |
| Country | Denmark | United States |
| Employees | 3029 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 14.7B |
| IPO Year | N/A | 1994 |
| Metric | GMAB | GGG |
|---|---|---|
| Price | $27.94 | $86.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $39.81 | ★ $95.25 |
| AVG Volume (30 Days) | ★ 1.5M | 861.4K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 9.22 |
| EPS | N/A | ★ 3.08 |
| Revenue | N/A | ★ $2,236,604,000.00 |
| Revenue This Year | $17.85 | $6.77 |
| Revenue Next Year | $16.04 | $4.86 |
| P/E Ratio | ★ $1.90 | $28.18 |
| Revenue Growth | N/A | ★ 5.83 |
| 52 Week Low | $18.89 | $77.19 |
| 52 Week High | $35.43 | $95.69 |
| Indicator | GMAB | GGG |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 50.19 |
| Support Level | $24.95 | $81.15 |
| Resistance Level | $29.86 | $88.15 |
| Average True Range (ATR) | 0.60 | 1.84 |
| MACD | 0.18 | 0.24 |
| Stochastic Oscillator | 54.42 | 59.83 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.2 billion in sales in 2025.